IDBS Blog | 28th June 2011
If You Think Enterprise ELNs Only Save Paper, Think Again
The switch from paper-based notebooks to Electronic Lab Notebooks has proved as profound as the move from 78rpm records to iTunes. To stay competitive in this increasingly data driven world, investing in ELNs is becoming more and more crucial.
Nowhere is that more true than in preclinical drug development.
In just five years the use of ELNs throughout late stage research, development and manufacturing, (dare I say, spearheaded by IDBS’ E-WorkBook), has led them to become enterprise systems offering everyone an easily mined and searchable rich data source.
Today’s advanced Enterprise ELNs integrate with existing LIMS to offer highly sophisticated and flexible data capture. Combining these systems removes bottlenecks typically found between disparate data sources and provides much faster access to raw scientific data and its context.
The business benefits are evident and proven – more effective collaboration, fast reporting and easier compliance with initiatives such as ‘Quality by Design’. That’s what I call a significant commercial advantage.
If ever there was a time to re-evaluate whether an ELN is the right system for you, it’s now.
More news
Ensuring product, process and patient data integrity and traceability throughout the BioPharmaceutical lifecycle in the era of personalized medicine
The BioPharma industry is facing a multitude of challenging external trends, from the growth in personalized medicine to supply chain disruptions and more.
European Biomanufacturing Summit 2023
Come and join us at booth 130 in Amsterdam, to learn how an innovative tech transfer approach can revolutionize drug manufacturing in the pharmaceutical industry.
IDBS events roundup: Q1 highlights and Q2 events
IDBS associates had the opportunity to attend some events in Q1 and attendees were eager to see, hear and learn more about what’s happening in the industry.
How to improve time-to-value using GxP computer systems
Explore the benefits of GxP computer systems to improve time-to-value so that companies can speed up the development and manufacture of life-saving drugs.